Higher macular volume in patients with MS receiving fingolimod: Positive outcome or side effect?

Neurology

Volumn 80, Issue 2, 2013, Pages 128-129

  Dinkin, Marc ^a   Paul, Friedemann ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD;

BRAIN ATROPHY; BRAIN WEIGHT; DISEASE DURATION; DRUG SAFETY; EDITORIAL; HUMAN; MACULAR THICKNESS; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA GANGLION CELL; RETINA INJURY; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINAL NERVE FIBER LAYER THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACULA LUTEA; MALE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84873645286     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827ccf4a     Document Type: Editorial

References (10)

1. Radue EW, O'Connor P, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 2012;69: 1259-1269.
2. Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 2013;80:139-144.
3. Serbecic N, Aboul-Enein F, Beutelspacher SC, et al. High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years. PLoS One 2011;6:e19843.
4. Frisén L, Hoyt WF. Insidious atrophy of retinal nerve fibers in multiple sclerosis: funduscopic identification in patients with and without visual complaints. Arch Ophthalmol 1974;92:91-97.
5. Green AJ, McQuaid S, Hauser SL. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain 2010;133(pt 6):1591-1601.
6. Gordon-Lipkin E, Chodkowski B, Reich DS, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007;69:1603-1609. (Pubitemid 350287144)
7. Burkholder BM, Osborne B, Loguidice MJ, et al. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol 2009;66:1366-1372.
8. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
9. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
10. Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012;135(pt 6):1786-1793.